Drug intelligence / Profile preview

ketoconazole + hydrocortisone + dutasteride

Development stage: Unknown
Lead developer: Dana-Farber Cancer Institute
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of ketoconazole, hydrocortisone, and dutasteride used primarily for the treatment of castration-resistant prostate cancer (CRPC). This regimen targets multiple steps in androgen synthesis: ketoconazole inhibits CYP17A1 to reduce androgen production, hydrocortisone replaces cortisol and prevents adrenal insufficiency, and dutasteride inhibits type I and II 5α-reductases to prevent conversion of testosterone to dihydrotestosterone.

Targets

CYP51A1 (Sterol 14α-demethylase)SRD5A2 (Steroid 5-alpha-reductase type II)SRD5A1 (Steroid 5-alpha-reductase type 1)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)

Beyond the preview

Go deeper on ketoconazole + hydrocortisone + dutasteride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketoconazole + hydrocortisone + dutasteride.

Explore the full profile